Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Beth Sheedy"'
5
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
Autor: Michael Jeffers, Karl D. Lewis, Daniel D. Von Hoff, Li Tain Yeh, Grace K. Dy, Prabhu Rajagopalan, Alex A. Adjei, Colin D. Weekes, Ramesh K. Ramanathan, S. Gail Eckhardt, Ronald L. Dubowy, Cory Iverson, Beth Sheedy, Neil J. Clendeninn, Jeffrey N. Miner, Wen Wee Ma, Zancong Shen, Lia Gore, Glen J. Weiss, Diane P. Leffingwell
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 19(5)
Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of BAY 86-9766, a selective, potent, orally available, small-molecule allosteric inhibitor of mitogen-activated protein kinase 1/2 in patients with advanced solid tumors. Experim
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9a785b43e0381eaac7d6ddca7cf435c
https://pubmed.ncbi.nlm.nih.gov/23434733
Zobrazit plný text záznamu
6
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects
Autor: Armin Rieger, Tranh Nguyen, Marta Boffito, Mai Nguyen, Zancong Shen, Voon Ong, Graeme Moyle, Barry D. Quart, Li-Tain Yeh, Vijay Hingorani, Anneke K. Raney, Beth Sheedy, Albrecht Stoehr, Kimberly Manhard
Publikováno v: Antimicrobial agents and chemotherapy. 54(8)
RDEA806 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. A phase 2a randomized, double-blind, placebo-controlled, dose-escalating study evaluated the short-ter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8edb08a6aacfdf62d5a490a31566465
https://pubmed.ncbi.nlm.nih.gov/20498326
Zobrazit plný text záznamu
7
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Autor: Darcy V. Spicer, Howard L. McLeod, Linda J. Paradiso, Stephen Shibata, Brenda Kyle, Beth Sheedy, Mary Carroll, John D. Roberts, Mary A. Collier, Yazdi K. Pithavala, Mary Beth Tombes, Neil J. Clendeninn
Publikováno v: Cancer chemotherapy and pharmacology. 45(5)
Purpose: To identify a recommended phase II dose for the second generation glycinamide ribonucleotide transformylase (GARFT) inhibitor, AG2034, administered by intravenous bolus every 3 weeks without folate supplementation and to describe AG2034 phar
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d50b35a97194657e5203eff8cdb6eee9
https://pubmed.ncbi.nlm.nih.gov/10803927
Zobrazit plný text záznamu
8
Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer
Autor: Lia Gore, W. W. Ma, Prabhu Rajagopalan, Michael Jeffers, Ronald L. Dubowy, Glen J. Weiss, L. Yeh, Zancong Shen, Beth Sheedy, R. K. Ramanathan, Diane P. Leffingwell, Grace K. Dy, Jeffrey N. Miner, Neil J. Clendeninn, Cory Iverson, Karl D. Lewis, Colin D. Weekes, D. D. Von Hoff, Araba A. Adjei
Publikováno v: Journal of Clinical Oncology. 29:3007-3007
3007 Background: BAY 86-9766 is a highly selective, allosteric inhibitor of MEK1/2. A phase I dose-escalation trial was conducted to determine the maximum tolerated dose (MTD), pharmacokinetics (PK) and pharmacodynamics (PD) in patients with advanced
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0bcf07ce347299bdc32a7430668c33d
https://doi.org/10.1200/jco.2011.29.15_suppl.3007
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje